COMPANY

Aridis Pharmaceuticals

HQ: Los Gatos, CA source · aridispharma.com ↗ · West Coast

Aridis’ proprietary mAb discovery platforms, ⅄PEX and MabIgX®, recover and immortalize the antibody-producing cells (called ‘B-cells’) from these individuals, turning them into therapeutic antibody producing factories. From company website Source · Oct 13, 2026

Keywords: antibody Cystic Fibrosis Ventilator Associated Pneumonia Staphylococcus Aureus Lung Infection Bacterial Infection Pseudomonas Aeruginosa Pneumonia Pneumonia Due to Staphylococcus Aureus Suvratoxumab AR-301 AR-105 KBSA301

Location: Los Gatos, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)18NIH grants

Timeline

Sep 2, 2022 Trial start Phase 3: A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 source ↗
May 3, 2019 Trial start Phase 3: Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 source ↗
Dec 7, 2018 Trial start Phase 1/Phase 2: SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects source ↗
Mar 29, 2017 Trial start Phase 2: Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia source ↗
2015-04 Trial start Phase 1: Study of Single Doses of IV Aerucin in Healthy Adults source ↗
2012-05 Trial start Phase 1/Phase 2: Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus) source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT05331885	A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2	Phase 3	Terminated	Sep 2, 2022	Jul 8, 2024 (actual)
NCT03816956	Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301	Phase 3	Completed	May 3, 2019	Oct 28, 2022 (actual)
NCT03669614	SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Dec 7, 2018	2023-07 (estimated)
NCT03027609	Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia	Phase 2	Completed	Mar 29, 2017	Apr 25, 2019 (actual)
NCT01589185	Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)	Phase 1/Phase 2	Completed	2012-05	2016-05 (actual)
NCT02486770	Study of Single Doses of IV Aerucin in Healthy Adults	Phase 1	Completed	2015-04	2015-09 (actual)

NIH awards 18

Annual award amounts. Total $12.7M.

2016 NIH contract (government contract; not a grant and not an investment round) 272201300016C-6-0-1 FY2016: $127,822 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 272201300016C-6-0-2 FY2016: $127,822 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 272201300016C-6-0-3 FY2016: $127,822 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
May 7, 2015 NIH award 5R43AI108083-02 FY2015: $282,803 awarded for that fiscal year; activity R43 (SBIR); PI TRUONG, VU L.; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Stable Vaccines Delivered on Oral Thin source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201300016C-1-0-1 FY2015: $700,798 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201300016C-1-0-2 FY2015: $620,545 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201300016C-1-0-3 FY2015: $620,545 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developmen source ↗
Jun 3, 2014 NIH award 1R43AI108083-01A1 FY2014: $283,500 awarded for that fiscal year; activity R43 (SBIR); PI TRUONG, VU L.; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Stable Vaccines Delivered on Oral Th source ↗
Jul 29, 2013 NIH award 5R42AI072866-05 FY2013: $999,998 awarded for that fiscal year; activity R42 (STTR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Human Monoclonal Antibody To Treat source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 272201300016C-0-0-1 FY2013: $4,784,675 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TRUONG, VU; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Developm source ↗
Jul 31, 2012 NIH award 5R42AI072866-04 FY2012: $999,998 awarded for that fiscal year; activity R42 (STTR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Human Monoclonal Antibody To Treat source ↗
Sep 19, 2011 NIH award 2R42AI072866-03 FY2011: $922,387 awarded for that fiscal year; activity R42 (STTR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Human Monoclonal Antibody To Treat source ↗
Aug 9, 2010 NIH award 5R43AI081400-02 FY2010: $299,869 awarded for that fiscal year; activity R43 (SBIR); PI TRUONG, VU L.; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Inhalable Gallium Nitrate Anti-Infecti source ↗
Jul 17, 2009 NIH award 1R43AI081400-01A1 FY2009: $299,960 awarded for that fiscal year; activity R43 (SBIR); PI TRUONG, VU L.; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Inhalable Gallium Nitrate Anti-Infec source ↗
Jul 2, 2008 NIH award 5R41AI072866-02 FY2008: $243,632 awarded for that fiscal year; activity R41 (STTR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, Los Gatos, CA. Human Monoclonal Antibody To Treat source ↗
Jul 11, 2007 NIH award 1R41AI072866-01A1 FY2007: $299,997 awarded for that fiscal year; activity R41 (STTR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, SAN JOSE, CA. Human Monoclonal Antibody To Trea source ↗
Aug 15, 2006 NIH award 5R43AI063829-02 FY2006: $501,698 awarded for that fiscal year; activity R43 (SBIR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, SAN JOSE, CA. Live, oral, heat Stable S. typhi TY source ↗
Aug 29, 2005 NIH award 1R43AI063829-01A1 FY2005: $472,908 awarded for that fiscal year; activity R43 (SBIR); PI PATZER, ERIC JOHN; recipient as written: ARIDIS PHARMACEUTICALS, LLC, SAN JOSE, CA. Live, oral, heat Stable S. typhi source ↗